アミオダロン

セダコロン · (2-ブチル-3-ベンゾフラニル)[4-[2-(ジエチルアミノ)エトキシ]-3,5-ジヨードフェニル]ケトン · (2-ブチルベンゾフラン-3-イル)[4-[2-(ジエチルアミノ)エトキシ]-3,5-ジヨードフェニル]メタノン · (2-ブチル-3-ベンゾフラニル)[4-[2-(ジエチルアミノ)エトキシ]-3,5-ジヨードフェニル]メタノン · アミオダロン · (2-ブチルベンゾフラン-3-イル)[3,5-ジヨード-4-[2-(ジエチルアミノ)エトキシ]フェニル]ケトン · (2-ブチルベンゾフラン-3-イル)-[4-(2-(ジエチルアミノ)エトキシ)-3,5-ジヨードフェニル]ケトン · 2-ブチル-3-ベンゾフラニル4-(2-ジエチルアミノエトキシ)-3,5-ジヨードフェニルケトン

https://huagongshe.com/ja/chemical/2157

識別子と物理属性

CAS No.	1951-25-3
分子式	C25H29I2NO3
平均分子量	645.3 g/mol
単同位体質量	645.02368979 g/mol
SMILES	CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1
InChIKey	IYIKLHRQXLHMJQ-UHFFFAOYSA-N
PubChem CID	2157
ChEMBL	CHEMBL633
ChEBI	CHEBI:2663
EC No.	217-772-1
DTXSID	DTXSID7022592
現地名	アミオダロン

化学・物理的性質

XLogP	7.6
極性表面積	42.7
水素結合供与体数	0
水素結合受容体数	4
回転可能結合数	11
重原子数	31
形式電荷	0
複雑度	547
医薬品	Pharmaceuticals -> Listed in ZINC15Pharmaceuticals -> Used in Switzerland
LogP（分配係数）	7.96.59
溶解度	Low4.76e-03 g/Lクロロホルム（微量）、メタノール（微量）716.4mg/L(25℃)
Human Drugs	Breast FeedingLactationMilk, HumanAntiarrhythmicsPharmaceuticalsAntiarrhythmic medicines
Endocrine Disruptors	Potential endocrine disrupting compound
Physical Description	Solid
Ionization Efficiency	Positive4.7016910252.7Thermo LTQElectrospray ionizationformic acid (5.3nM)
Dissociation Constants	9.066.56 ± 0.06
Collision Cross Section	223.8 Å² [M+H]+ [CCS Type: DTBuffer gas: N2Ionization: APCI+Dataset: TOXCASTSource Identifier: DTXSID7037185]224.84 Å² [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]226.4 Å² [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)]
融点	54 - 55°C
沸点	635.1±55.0 °C(Predicted)
密度	1.5730 (estimate)
貯蔵条件	2-8°C
外観・状態	個体
pKa（酸解離定数）	6.56(at 25℃)
色	無色～淡黄色オイル～
安定性	安定。強力な酸化剤とは相容れない。
InChI	InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3
InChIKey	IYIKLHRQXLHMJQ-UHFFFAOYSA-N
SMILES	C(C1C2=CC=CC=C2OC=1CCCC)(C1=CC(I)=C(OCCN(CC)CC)C(I)=C1)=O
CAS データベース	1951-25-3(CAS DataBase Reference)
EPAの化学物質情報	Methanone, (2-butyl-3-benzofuranyl)[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]- (1951-25-3)

安全性と法規制

GHS 分類	This chemical does not meet GHS hazard criteria for 96.4% (53 of 55) of all reports.Not ClassifiedAggregated GHS information provided per 55 reports by companies from 3 notifications to the ECHA C&L Inventory.
規制情報	Amiodarone: Does not have an individual approval but may be used under an appropriate group standard
その他の安全情報	IMAP assessments - Methanone, (2-butyl-3-benzofuranyl)[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]-: Human health tier I assessment
Hazard Classes and Categories	Not Classified
健康影響	Some side effects have a significant mortality rate: specifically, hepatitis, exacerbation of asthma and congestive failure, and pneumonitis.
Hepatotoxicity	While liver injury from amiodarone is uncommon, it is not rare. Serum enzyme elevations are reported to occur in 15% to 50% of patients on long term therapy, but with lower doses (200 to 300 mg daily), ALT elevations are less common. Often these elevations resolve despite continuation of amiodarone, and liver biopsy may reveal minimal changes, or accumulation of granular material in macrophages without other evidence of injury. Patients taking amiodarone are recommended to have ALT and AST values taken at baseline and then every six months, and to discontinue therapy if levels are persistently greater than twice the upper limit of the normal range. The efficacy of this approach, even if followed, in preventing serious liver injury from amiodarone is unclear.
有害作用	Adverse effects from amiodarone therapy can be as high as 15% within the initial year of use and may reach 50% with long-term treatment. The risk-to-benefit ratio frequently results in the discontinuation of amiodarone within the first year of treatment, particularly for patients with atrial fibrillation. The most prevalent adverse effect is the development of corneal microdeposits, which occur in at least 90% of patients taking amiodarone. This occurrence is believed to result from amiodarone being secreted in the lacrimal gland and subsequently taken up by the corneal epithelium. However, only about 10% of these patients will develop actual visual symptoms. Additional ocular adverse effects include photophobia, optic neuropathy, and visual halos. A baseline ophthalmological assessment is recommended for patients initiating amiodarone therapy.
暴露経路	Slow and variable (about 20 to 55% of an oral dose is absorbed).

用途

カリウムチャネル抑制薬（Ⅲ群薬）抗不整脈薬

説明

From the chemical point of view, amiodarone is completely different from other antiarrhythmics. It has two iodide atoms and a diethylaminoethanol group as substituents in the benzoyl part, and overall it is very similar to the structure of thyroxin-like molecules.

使用

antibacterial

一般的な説明

Amiodarone, 2-butyl-3-benzofuranyl-4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl ketone (Cordarone),was introduced as an antianginal agent. It has very pronouncedclass III action and is especially effective in maintainingsinus rhythm in patients who have been treated bydirect current shock for atrial fibrillation. Like class IIIantiarrhythmic drugs, amiodarone lengthens the effective refractoryperiod by prolonging the action potential duration inall myocardial tissues. Amiodarone is eliminated very slowlyfrom the body, with a half-life of about 25 to 30 days after oraldoses. Although the drug has a broad spectrum of antiarrhythmicactivity, its main limitation is a slow onset of action.Drug action may not be initiated for several days, and thepeak effect may not be obtained for several weeks.